Publications by authors named "Karen D Boyle"
BackgroundIL-6 receptor (IL-6R) signaling drives development of T cell populations important to type 1 diabetes pathogenesis. We evaluated whether blockade of IL-6R with monoclonal antibody tocilizumab would slow loss of residual β cell function in newly diagnosed type 1 diabetes patients.MethodsWe conducted a multicenter, randomized, placebo-controlled, double-blind trial with tocilizumab in new-onset type 1 diabetes.
View Article and Find Full Text PDFArticle Synopsis
- Trials of immune therapies for new-onset Type 1 Diabetes (T1D) show promise, but results vary among patients and don't last long.
- This study tested two courses of teplizumab, an anti-CD3 monoclonal antibody, on 52 T1D patients to see if it slows the decline in insulin production (C-peptide levels) after 2 years.
- Results indicated that teplizumab significantly reduced C-peptide decline by 75% compared to control, with common side effects including rash and headache, and identified specific metabolic and immunologic traits that help predict which patients respond well to the treatment.
Rapamycin/interleukin-2 (IL-2) combination treatment of NOD mice effectively treats autoimmune diabetes. We performed a phase 1 clinical trial to test the safety and immunologic effects of rapamycin/IL-2 combination therapy in type 1 diabetic (T1D) patients. Nine T1D subjects were treated with 2-4 mg/day rapamycin orally for 3 months and 4.
View Article and Find Full Text PDF